Browse Articles

Lutetium PSMA is approved for the treatment of advanced prostate cancer and is being studied in a neoadjuvant setting. The influence of lutetium PSMA on the tumour immune microenvironment is unknown. In selected patients, lutetium PSMA could be used as a stand-alone treatment or in combination with immunotherapy to produce long-lasting antitumour immunity.

In this Review, the authors provide an overview of currently available genomic and transcriptomic biomarkers of non-muscle-invasive bladder cancer progression. Both single-gene biomarkers and gene signature are discussed, with the aim of identifying markers close to clinical implementation and providing insights for future research in this field.

Pelvic lymph node dissection is performed for staging and to prevent recurrence of prostate cancer; however, immune checkpoint inhibition could be affected by lymph node removal. Here, the authors discuss the possibility that lymph nodes could be ‘friends’ rather than ‘foes’ in prostate cancer treatment.

Paternal origins of health and disease is an emerging paradigm highlighting the influence of paternal environmental exposures, including diet and lifestyle, on offspring health. The influence of the paternal gut microbiota on the germ line and offspring outcomes has been investigated in a new study.

Cystoscopy and transurethral resection of the bladder tumour are crucial in bladder cancer diagnosis, treatment and surveillance. Advances in enhanced cystoscopy technologies and artificial intelligence offer promising avenues to address the unmet need to improve tumour delineation and resection.

This review explores the basic biology of prostate-specific membrane antigen (PSMA) and its growing significance in molecular imaging and treatment. It emphasizes the importance of understanding PSMA regulation and heterogeneity for the effective application of PSMA-targeted radioligand therapy.

In this Perspective, the authors provide an overview of current research using CRISPR–Cas gene editing technologies to understand biological mechanisms and identify novel therapeutic targets in muscle-invasive bladder cancer. Future perspectives about the use of CRISPR-based therapeutics in the clinic, as well as current limitations and ethical considerations, are also discussed.

Reprogrammed metabolism has been long recognized as a driver of kidney cancer progression, prompting efforts to develop metabolic targeted therapies against this disease. Evidence offers further clarity on the metabolic phenotypes associated with aggressive disease, expanding the potential target space for attacking these tumours at their metabolic roots.

Partial nephrectomy aims to provide both effective oncological management and renal function preservation. Surgical complications pertaining to the defect created during a partial nephrectomy include haemorrhage and urinary leak. We explore advances in techniques for managing the defect created during a partial nephrectomy (renorrhaphy).

In this Review, the authors discuss advantages and complications associated with renal mass biopsy and provide an overview of different features of both well-recognized types of renal cell carcinoma and newly identified subtypes to improve diagnosis and management.

Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic development of prostate cancer treatments. Previously, overall survival was a requirement for approvals. Whether this approach is warranted or beneficial to patients remains unclear.